Solvonis TherapeuticsLSE: SVNS
Also known as: Graft Polymer (UK) PLC, Awakn Life Sciences Corp
Solvonis Therapeutics plc (LSE: SVNS) is a London-listed, clinical-stage biopharmaceutical company developing evidence-based treatments for addiction and mental health disorders. Formed through the rebranding of Graft Polymer (UK) PLC and the acquisition of Awakn Life Sciences Corp (NEO: AWKN, completed May 2025), Solvonis inherited Awakn's lead programme SVN-001 — IV ketamine combined with manualised CBT — now in Phase 3 for severe alcohol use disorder, co-funded by the UK NIHR. The company also advances SVN-002 (buccal/sublingual esketamine for US AUD) and SVN-SDN-14 (novel SDN receptor modulators for PTSD at preclinical stage), plus an AI-driven CNS discovery engine.
Drug Pipeline
4SVN-001
KetamineSevere AUD. IV ketamine + manualised CBT ('More Kare' Phase 3, n=280, two-armed active placebo-controlled; co-funded by UK NIHR EME Programme NIHR150193, University of Exeter CTU). Started Q3 2024, completion expected late 2026/early 2027. Phase 2: 86% abstinence at 6 months vs 2% pre-trial. Originally AWKN-001 at Awakn Life Sciences.
SVN-002
EsketamineModerate-to-severe AUD (US). Proprietary sublingual/buccal esketamine + manualised therapy, IND-ready for Phase 2b under FDA 505(b)(2) pathway. PK studies ongoing; initial data expected early 2026.
SVN-SDN-14
PTSD. Novel serotonin/dopamine/noradrenaline (SDN) receptor modulators targeting pro-social behaviour with improved safety vs existing PTSD treatments. US patent allowed (composition of matter, Jan 2026). Lead candidate selection in progress.
SVN-015
Stimulant use disorder (methamphetamine and cocaine). Accepted into US NIDA Addiction Treatment Discovery Program (Dec 2025); NIDA funding early safety/pharmacology studies. Results expected Q1 2026.
Quick Facts
- Type
- Public Biotech
- Founded
- 2020
- Ticker
- LSE: SVNS
- Lead Stage
- Phase III
- HQ
- Eccleston Yards, 25 Eccleston Place, London SW1W 9NF, UK, United Kingdom
- Website
- Visit